No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
(2r)-2-propyloctanoic acid |
- |
- |
- |
- |
1件: 2 |
2 |
(r)-(-)-2-propyloctaroic acid |
- |
- |
- |
- |
1件: 2 |
3 |
1.0 miu il-2 per day |
Human interleukin-2 |
- |
- |
- |
1件: 2 |
4 |
2.0 miu il-2 per day |
Human interleukin-2 |
- |
- |
- |
1件: 2 |
5 |
250 mg ck-2017357 |
- |
- |
- |
- |
2件: 2, 11 |
6 |
4-cholesten-3-one, oxime |
- |
- |
- |
- |
2件: 2, 3 |
7 |
40 mg ga |
- |
- |
- |
- |
2件: 2, 13 |
8 |
40 mg glatiramer acetate |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
2件: 2, 13 |
9 |
5% glucose water solution |
Water |
D00001 |
- |
- |
1件: 2 |
10 |
500 mg ck-2017357 |
- |
- |
- |
- |
2件: 2, 11 |
11 |
[18f] ge-180 |
- |
- |
- |
- |
1件: 2 |
12 |
[18f]dpa-714 pet |
- |
- |
- |
- |
1件: 2 |
13 |
[18f]pbr06 |
- |
- |
- |
- |
1件: 2 |
14 |
[i-123] adam |
Iodide i-123 |
- |
- |
- |
1件: 2 |
15 |
Ab1010 |
Masitinib |
D10229 |
1件: KIT |
11件: Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway |
6件: 2, 5, 6, 13, 46, 96 |
16 |
Acetate |
Acetate |
- |
- |
- |
40件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
17 |
Acetylcarnitine |
Acetylcarnitine |
- |
- |
- |
2件: 2, 265 |
18 |
Acthar |
Corticotropin |
D00146 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
6件: 2, 13, 46, 49, 50, 222 |
19 |
Actos 15 mg |
Pioglitazone |
D00945, D08378 |
1件: PPARG |
9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
1件: 2 |
20 |
Actos 30 mg |
Pioglitazone |
D00945, D08378 |
1件: PPARG |
9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
1件: 2 |
21 |
Actos 45 mg |
Pioglitazone |
D00945, D08378 |
1件: PPARG |
9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
1件: 2 |
22 |
Albumin |
- |
- |
- |
- |
2件: 2, 51 |
23 |
Albutein 5% |
Human serum albumin |
D05424 |
- |
- |
1件: 2 |
24 |
Albúmina humana |
- |
- |
- |
- |
1件: 2 |
25 |
Alpha-lipoic acid |
Lipoic acid |
D00048, D00086 |
- |
- |
2件: 2, 13 |
26 |
Amivita |
- |
- |
- |
- |
1件: 2 |
27 |
Amsc |
- |
- |
- |
- |
1件: 2 |
28 |
Amx0035 |
- |
- |
- |
- |
1件: 2 |
29 |
Anakinra |
Anakinra |
D02934 |
2件: IL1R1, IL1R2 |
15件: Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer |
15件: 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 84, 86, 106, 107, 299 |
30 |
Ap-101 |
- |
- |
- |
- |
1件: 2 |
31 |
Apo-p001 |
- |
- |
- |
- |
1件: 2 |
32 |
Arimoclomol |
Arimoclomol |
D11374 |
- |
- |
3件: 2, 15, 19 |
33 |
Arundic acid |
Arundic acid |
D06296 |
- |
- |
1件: 2 |
34 |
Astrorx |
- |
- |
- |
- |
1件: 2 |
35 |
Autologous adipose-derived mesenchymal stromal cells |
- |
- |
- |
- |
1件: 2 |
36 |
Autologous bone marrow mononucleated cells |
- |
- |
- |
- |
1件: 2 |
37 |
Autologous bone marrow-derived stem cells |
- |
- |
- |
- |
1件: 2 |
38 |
Autologous mesenchymal stem cells |
- |
- |
- |
- |
5件: 2, 6, 13, 17, 46 |
39 |
Autologous mesenchymal stem cells (mscs) |
- |
- |
- |
- |
1件: 2 |
40 |
Autologous msc-ntf cells |
- |
- |
- |
- |
1件: 2 |
41 |
Autologous t-regulatory lymphocytes |
- |
- |
- |
- |
1件: 2 |
42 |
Avp-923 |
- |
- |
- |
- |
3件: 2, 6, 13 |
43 |
Azilect® 1 mg tabletten |
Rasagiline |
D02562, D08469, D10829 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 2 |
44 |
Baclofen |
Baclofen |
D00241 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
5件: 2, 10, 13, 18, 149 |
45 |
Basiliximab |
Basiliximab |
D03058 |
1件: IL2RA |
11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
6件: 2, 50, 65, 97, 222, 228 |
46 |
Betamethasone |
Betamethasone |
D00244, D00972, D01357, D01402, D01637, D02032, D02286 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
6件: 2, 46, 65, 90, 96, 235 |
47 |
Betamethasone sodium phosphate/betamethasone acetate (celestone® soluspan®), 30 mg im once a day for four days |
Betamethasone |
D00244, D00972, D01357, D01402, D01637, D02032, D02286 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 2 |
48 |
Bhv-0223 |
- |
- |
- |
- |
1件: 2 |
49 |
Biib050 / kns-760704 |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 2 |
50 |
Biib050/kns-760704 |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 2 |
51 |
Biib067 |
- |
- |
- |
- |
1件: 2 |
52 |
Biib078 |
- |
- |
- |
- |
1件: 2 |
53 |
Biib100 |
- |
- |
- |
- |
1件: 2 |
54 |
Biologic: ic14 (monoclonal antibody against human cd14) |
- |
- |
- |
- |
1件: 2 |
55 |
Biotin |
Biotin |
D00029 |
- |
- |
3件: 2, 13, 20 |
56 |
Blood sample and environmental survey |
- |
- |
- |
- |
1件: 2 |
57 |
Blz945 |
- |
- |
- |
- |
1件: 2 |
58 |
Bosutinib |
Bosutinib |
D03252 |
2件: ABL1, SRC |
45件: Adherens junction, Axon guidance, Bacterial invasion of epithelial cells, Bladder cancer, C-type lectin receptor signaling pathway, Cell cycle, Chemokine signaling pathway, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, GABAergic synapse, Gap junction, GnRH signaling pathway, Hepatitis B, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, MicroRNAs in cancer, Mitophagy - animal, Neurotrophin signaling pathway, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Prolactin signaling pathway, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis, Thyroid hormone signaling pathway, Tight junction, Tuberculosis, VEGF signaling pathway, Viral carcinogenesis, Viral myocarditis, Yersinia infection |
2件: 2, 67 |
59 |
Botox 100 unites allergan (pr1) |
Botulinum toxin type a |
D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
1件: 2 |
60 |
Botox injection |
- |
- |
- |
- |
1件: 2 |
61 |
Botulinum toxin type a |
Botulinum toxin type a |
D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
10件: 2, 5, 6, 7, 13, 15, 17, 70, 113, 149 |
62 |
Botulinum toxin type b |
Botulinum toxin type b |
D02735 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
3件: 2, 6, 51 |
63 |
Botulinum toxin type b (myobloc) |
Botulinum toxin type b |
D02735 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
2件: 2, 6 |
64 |
Brx-345 |
- |
- |
- |
- |
1件: 2 |
65 |
Butylphthalide |
Butylphthalide |
- |
- |
- |
2件: 2, 6 |
66 |
Caffeine |
Caffeine |
D00528, D01453 |
11件: ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A |
22件: Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
6件: 2, 6, 46, 78, 96, 97 |
67 |
Calogen |
- |
- |
- |
- |
1件: 2 |
68 |
Cannabis |
Medical cannabis |
- |
- |
- |
6件: 2, 6, 13, 90, 96, 97 |
69 |
Cannabis sativa extract oromucosal spray |
Medical cannabis |
- |
- |
- |
1件: 2 |
70 |
Cannabis, medical |
Medical cannabis |
- |
- |
- |
5件: 2, 6, 13, 96, 97 |
71 |
Canntrust cbd oil (capsule) |
- |
- |
- |
- |
1件: 2 |
72 |
Capsaicin |
Capsaicin |
D00250 |
1件: TRPV1 |
2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
6件: 2, 6, 19, 86, 113, 226 |
73 |
Capsaicin challenge |
Capsaicin |
D00250 |
1件: TRPV1 |
2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
1件: 2 |
74 |
Carbidopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
8件: 2, 4, 6, 13, 17, 90, 164, 201 |
75 |
Carbidopa-levodopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
3件: 2, 4, 6 |
76 |
Carbolithium |
- |
- |
- |
- |
1件: 2 |
77 |
Carbolithium*100cps 150mg |
- |
- |
- |
- |
1件: 2 |
78 |
Carbonate |
Carbonate ion |
- |
- |
- |
10件: 2, 13, 17, 19, 46, 75, 96, 127, 235, 299 |
79 |
Carbonate de lithium |
Carbonate ion |
- |
- |
- |
1件: 2 |
80 |
Cc100 |
- |
- |
- |
- |
1件: 2 |
81 |
Ceftriaxone |
Ceftriaxone |
D00924, D07659 |
- |
- |
3件: 2, 6, 97 |
82 |
Celecoxib |
Celecoxib |
D00567 |
1件: PTGS2 |
20件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
8件: 2, 3, 34, 46, 70, 89, 161, 271 |
83 |
Cell-based therapeutics |
- |
- |
- |
- |
1件: 2 |
84 |
Cell-based therapy |
- |
- |
- |
- |
1件: 2 |
85 |
Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in als patients |
- |
- |
- |
- |
1件: 2 |
86 |
Cimetidine |
Cimetidine |
D00295, D03503 |
1件: HRH2 |
3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction |
1件: 2 |
87 |
Cimetidine plus dexpramipexole |
Dexpramipexole |
D09886 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 2 |
88 |
Ciprofloxacin |
Ciprofloxacin |
D00186, D02216 |
- |
- |
5件: 2, 60, 96, 97, 299 |
89 |
Cistanche total glycosides |
- |
- |
- |
- |
1件: 2 |
90 |
Ck-2017357 |
- |
- |
- |
- |
1件: 2 |
91 |
Ck-2017357 (part a) |
- |
- |
- |
- |
1件: 2 |
92 |
Ck-2017357 (part b) |
- |
- |
- |
- |
1件: 2 |
93 |
Ck-2127107 |
Reldesemtiv |
D11363 |
1件: TNNC2 |
1件: Calcium signaling pathway |
2件: 2, 3 |
94 |
Cnm-au8 |
- |
- |
- |
- |
2件: 2, 13 |
95 |
Coenzyme q10 |
Ubidecarenone |
D01065 |
- |
- |
10件: 2, 6, 8, 10, 46, 57, 113, 193, 214, 215 |
96 |
Colchicina |
Colchicine |
D00570 |
9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 |
3件: Gap junction, Pathogenic Escherichia coli infection, Phagosome |
1件: 2 |
97 |
Colchicina lirca - 1 mg compresse 60 compresse |
Colchicine |
D00570 |
9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 |
3件: Gap junction, Pathogenic Escherichia coli infection, Phagosome |
1件: 2 |
98 |
Colchicine |
Colchicine |
D00570 |
9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 |
3件: Gap junction, Pathogenic Escherichia coli infection, Phagosome |
5件: 2, 42, 56, 93, 266 |
99 |
Colchicine 1 mg oral tablet |
Colchicine |
D00570 |
9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 |
3件: Gap junction, Pathogenic Escherichia coli infection, Phagosome |
1件: 2 |
100 |
Copegus |
Ribavirin |
D00423 |
- |
- |
1件: 2 |
101 |
Copper |
Copper |
- |
- |
- |
4件: 2, 169, 170, 171 |
102 |
Corticotropin |
Corticotropin |
D00146 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
7件: 2, 13, 46, 75, 78, 84, 222 |
103 |
Creatine |
Creatine |
- |
- |
- |
12件: 1, 2, 5, 6, 8, 13, 46, 49, 50, 113, 156, 201 |
104 |
Creatine monohydrate |
Creatine |
- |
- |
- |
4件: 2, 8, 113, 156 |
105 |
Creatinine |
Creatinine |
D03600 |
- |
- |
3件: 2, 46, 60 |
106 |
Cu(ii)atsm |
- |
- |
- |
- |
2件: 2, 6 |
107 |
Células madre mesenquimales de tejido adiposo autólogo |
- |
- |
- |
- |
1件: 2 |
108 |
Células mesenquimales de tejido adiposo |
- |
- |
- |
- |
1件: 2 |
109 |
Células troncales hematopoyéticas autólogas adultas extraidas de médula ósea |
- |
- |
- |
- |
1件: 2 |
110 |
Daraprim |
Pyrimethamine |
D00488 |
- |
- |
2件: 2, 4 |
111 |
Darunavir |
Darunavir |
D03656 |
- |
- |
1件: 2 |
112 |
Datscan |
Ioflupane i-123 |
D10014 |
- |
- |
3件: 2, 5, 6 |
113 |
Deferiprone |
Deferiprone |
D07416 |
- |
- |
5件: 2, 6, 120, 122, 233 |
114 |
Dexdor |
- |
- |
- |
- |
4件: 2, 4, 6, 70 |
115 |
Dexmedetomidine |
Dexmedetomidine |
D00514, D01205 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
11件: 2, 4, 6, 21, 34, 70, 113, 212, 215, 226, 280 |
116 |
Dexpramipexole |
Dexpramipexole |
D09886 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 2 |
117 |
Dexpramipexole (dose 1) |
Dexpramipexole |
D09886 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 2 |
118 |
Dexpramipexole (dose 2) |
Dexpramipexole |
D09886 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 2 |
119 |
Dexpramipexole dichydrochloride |
Dexpramipexole |
D09886 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 2 |
120 |
Dextran |
Dextran |
D00060 |
- |
- |
5件: 2, 62, 79, 96, 97 |
121 |
Dextran sulfate sodium |
Dextran |
D00060 |
- |
- |
1件: 2 |
122 |
Dextromethorphan |
Dextromethorphan |
D00848, D03742, D03744 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
9件: 2, 6, 8, 13, 46, 78, 96, 97, 156 |
123 |
Dextromethorphan hbr and quinidine sulfate |
Dextromethorphan |
D00848, D03742, D03744 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 2 |
124 |
Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg |
Dextromethorphan |
D00848, D03742, D03744 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
2件: 2, 13 |
125 |
Dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg |
Dextromethorphan |
D00848, D03742, D03744 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
2件: 2, 13 |
126 |
Dnl747 |
- |
- |
- |
- |
1件: 2 |
127 |
Dolutegravir |
Dolutegravir |
D10066 |
- |
- |
1件: 2 |
128 |
Dronabinol |
Dronabinol |
D00306 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
5件: 2, 13, 46, 271, 298 |
129 |
Drug: f 18 t807 |
- |
- |
- |
- |
1件: 2 |
130 |
E0302 (mecobalamin) |
Methylcobalamin |
D03246 |
- |
- |
1件: 2 |
131 |
Ebixa |
Memantine |
D04905, D08174 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
3件: 2, 6, 13 |
132 |
Edaravone |
Edaravone |
D01552 |
- |
- |
2件: 2, 22 |
133 |
Endocannabinoid palmitoylethanolamide (pea) |
Palmidrol |
D08328 |
- |
- |
1件: 2 |
134 |
Eperisone |
Eperisone |
D01671, D07898 |
- |
- |
1件: 2 |
135 |
Epi-589 |
- |
- |
- |
- |
2件: 2, 6 |
136 |
Eprex |
Erythropoietin |
D03231 |
1件: EPOR |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
1件: 2 |
137 |
Eprex iv sc 1fl 1ml 40000 ui |
Erythropoietin |
D03231 |
1件: EPOR |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
1件: 2 |
138 |
Eprex*1sir 40000ui/ml 1ml |
Erythropoietin |
D03231 |
1件: EPOR |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
1件: 2 |
139 |
Erythropoietin |
Erythropoietin |
D03231 |
1件: EPOR |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
8件: 2, 6, 13, 22, 47, 70, 95, 96 |
140 |
Escitalopram |
Escitalopram |
D02567, D07704, D07913 |
1件: SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
3件: 2, 6, 13 |
141 |
Esketamine |
Esketamine |
D07283 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
3件: 2, 4, 70 |
142 |
Ezogabine |
Ezogabine |
D09569 |
5件: KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5 |
6件: Adrenergic signaling in cardiomyocytes, Cholinergic synapse, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Vibrio cholerae infection |
2件: 2, 144 |
143 |
Fasudil |
Fasudil |
D07941 |
2件: ROCK1, ROCK2 |
22件: Axon guidance, Chemokine signaling pathway, Focal adhesion, Human cytomegalovirus infection, Leukocyte transendothelial migration, MicroRNAs in cancer, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Proteoglycans in cancer, Regulation of actin cytoskeleton, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, TGF-beta signaling pathway, Tight junction, Vascular smooth muscle contraction, Wnt signaling pathway, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 2 |
144 |
Febuxostat |
Febuxostat |
D01206 |
1件: XDH |
5件: Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome, Purine metabolism |
3件: 2, 6, 13 |
145 |
Fecal microbiota transplantation |
- |
- |
- |
- |
5件: 2, 66, 94, 96, 97 |
146 |
Filgrastim |
Filgrastim |
D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
25件: 2, 6, 13, 25, 26, 28, 34, 35, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 96, 113, 164, 283, 284, 285, 331 |
147 |
Fixed dose combination ciprofloxacin/celecoxib |
Ciprofloxacin |
D00186, D02216 |
- |
- |
1件: 2 |
148 |
Flx-787-odt |
- |
- |
- |
- |
1件: 2 |
149 |
Flx-787-odt (orally disintigrating tablet) |
- |
- |
- |
- |
1件: 2 |
150 |
Fycompa |
Perampanel |
D08964 |
4件: GRIA1, GRIA2, GRIA3, GRIA4 |
13件: Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Transcriptional misregulation in cancer, cAMP signaling pathway |
2件: 2, 144 |
151 |
Gdc-0134 |
- |
- |
- |
- |
1件: 2 |
152 |
Gilenya |
Fingolimod |
D10001 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
2件: 2, 13 |
153 |
Glatiramer |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
4件: 2, 13, 96, 156 |
154 |
Gm604 |
- |
- |
- |
- |
1件: 2 |
155 |
Gold |
Gold |
- |
- |
- |
5件: 2, 6, 13, 46, 171 |
156 |
Gold nanocrystals |
Gold |
- |
- |
- |
3件: 2, 6, 13 |
157 |
Granulocyte colony stimulating factor |
Filgrastim |
D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
3件: 2, 36, 85 |
158 |
Growth hormone |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
11件: 2, 13, 19, 46, 78, 96, 191, 193, 195, 265, 299 |
159 |
Growth hormone (somatropin) |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
2件: 2, 78 |
160 |
Gsk1223249 |
- |
- |
- |
- |
2件: 2, 13 |
161 |
Guana2015 |
- |
- |
- |
- |
1件: 2 |
162 |
Guanabenz |
Guanabenz |
D04375 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
2件: 2, 13 |
163 |
Guanabenz acetato |
Guanabenz |
D04375 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
1件: 2 |
164 |
Hk-001 |
- |
- |
- |
- |
1件: 2 |
165 |
Human albumin |
Human serum albumin |
D05424 |
- |
- |
1件: 2 |
166 |
Human albumin solution |
Human serum albumin |
D05424 |
- |
- |
1件: 2 |
167 |
Human autologous mesenchymal stem cells |
- |
- |
- |
- |
2件: 2, 13 |
168 |
Human neural stem cells |
- |
- |
- |
- |
2件: 2, 13 |
169 |
Hynr-cs inj |
- |
- |
- |
- |
1件: 2 |
170 |
Hynrcs-allo inj |
- |
- |
- |
- |
1件: 2 |
171 |
I-123 |
Iodide i-123 |
- |
- |
- |
2件: 2, 6 |
172 |
Ibudilast |
Ibudilast |
D01385 |
8件: CYSLTR1, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PTGIR |
16件: Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action, Platelet activation, Progesterone-mediated oocyte maturation, Purine metabolism, Regulation of lipolysis in adipocytes, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
2件: 2, 13 |
173 |
Ic14 |
- |
- |
- |
- |
1件: 2 |
174 |
Il-2 |
Human interleukin-2 |
- |
- |
- |
5件: 2, 46, 49, 56, 96 |
175 |
Immunoglobulin g1, anti (protein nogo a) (human mus musculus monoclonal heavy chain), disulfide with human mus musculus monoclonal light chain, dimer |
- |
- |
- |
- |
1件: 2 |
176 |
Incobotulinum toxin a |
- |
- |
- |
- |
2件: 2, 6 |
177 |
Inosine |
Inosine |
D00054 |
- |
- |
4件: 2, 6, 13, 17 |
178 |
Insulin like growth factor, type 1 |
- |
- |
- |
- |
1件: 2 |
179 |
Interleukin-2 |
Human interleukin-2 |
- |
- |
- |
6件: 2, 35, 49, 55, 65, 97 |
180 |
Intra venous injection of stem cell |
- |
- |
- |
- |
1件: 2 |
181 |
Intrathecal autologous stem cell |
- |
- |
- |
- |
1件: 2 |
182 |
Intrathecal injection |
- |
- |
- |
- |
1件: 2 |
183 |
Intravenous administration of 1 million of msc |
- |
- |
- |
- |
1件: 2 |
184 |
Intravenous administration of 2 million of msc |
- |
- |
- |
- |
1件: 2 |
185 |
Intravenous administration of 4 million of msc |
- |
- |
- |
- |
1件: 2 |
186 |
Intravenous immunoglobulin |
Immune globulin human |
- |
- |
- |
16件: 2, 11, 14, 17, 18, 35, 38, 39, 49, 51, 63, 65, 85, 164, 296, 309 |
187 |
Intraventricular injection |
- |
- |
- |
- |
1件: 2 |
188 |
Ioflupane 123i |
Ioflupane i-123 |
D10014 |
- |
- |
1件: 2 |
189 |
Ipl344 |
- |
- |
- |
- |
1件: 2 |
190 |
Isis 333611 |
- |
- |
- |
- |
1件: 2 |
191 |
Jevity 1.0 |
- |
- |
- |
- |
1件: 2 |
192 |
Jevity 1.5 |
- |
- |
- |
- |
1件: 2 |
193 |
Ketanest-s |
- |
- |
- |
- |
3件: 2, 4, 70 |
194 |
Ketocal |
- |
- |
- |
- |
1件: 2 |
195 |
Kns-760704 |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 2 |
196 |
L-serine |
Serine |
D00016 |
- |
- |
1件: 2 |
197 |
Lacosamide |
Lacosamide |
D07299 |
2件: SCN3A, SCN9A |
1件: Taste transduction |
3件: 2, 46, 149 |
198 |
Lactose |
Lactose |
D00046, D03226 |
- |
- |
6件: 2, 6, 13, 97, 228, 310 |
199 |
Lenograstim |
Lenograstim |
D03247 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
3件: 2, 57, 65 |
200 |
Leuprolide |
Leuprolide |
D00989, D08113 |
1件: GNRHR |
2件: GnRH signaling pathway, Neuroactive ligand-receptor interaction |
5件: 1, 2, 3, 51, 76 |
201 |
Levetiracetam |
Levetiracetam |
D00709 |
1件: SV2A |
1件: ECM-receptor interaction |
4件: 2, 4, 6, 13 |
202 |
Levodopa |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
7件: 2, 4, 6, 17, 90, 164, 201 |
203 |
Levosimendan |
Levosimendan |
D04720 |
2件: PDE3A, PDE3B |
11件: Apelin signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Progesterone-mediated oocyte maturation, Purine metabolism, Regulation of lipolysis in adipocytes, Renin secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 2 |
204 |
Lioresal*50cpr 10mg |
Baclofen |
D00241 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
1件: 2 |
205 |
Lipoic acid |
Lipoic acid |
D00048, D00086 |
- |
- |
5件: 2, 5, 13, 14, 20 |
206 |
Lithium |
Lithium citrate |
D04749 |
- |
- |
4件: 2, 5, 7, 8 |
207 |
Lithium carbonate |
Lithium carbonate |
D00801 |
- |
- |
5件: 2, 13, 17, 19, 127 |
208 |
Lithiumcarbonaat |
- |
- |
- |
- |
1件: 2 |
209 |
Lithiumcarbonaat 400 pch tabletten |
- |
- |
- |
- |
1件: 2 |
210 |
Litio carbonato |
- |
- |
- |
- |
1件: 2 |
211 |
Lunasin regimen |
- |
- |
- |
- |
1件: 2 |
212 |
Mannitolo 18% |
- |
- |
- |
- |
1件: 2 |
213 |
Mannitolo 18% ldb |
- |
- |
- |
- |
1件: 2 |
214 |
Masitinib |
Masitinib |
D10229 |
1件: KIT |
11件: Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway |
6件: 2, 5, 6, 13, 46, 96 |
215 |
Masitinib (3.0) |
Masitinib |
D10229 |
1件: KIT |
11件: Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway |
1件: 2 |
216 |
Masitinib (4.5) |
Masitinib |
D10229 |
1件: KIT |
11件: Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway |
1件: 2 |
217 |
Masitinib (6.0) |
Masitinib |
D10229 |
1件: KIT |
11件: Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway |
1件: 2 |
218 |
Masitinib mesylate |
Masitinib |
D10229 |
1件: KIT |
11件: Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway |
6件: 2, 5, 6, 13, 46, 96 |
219 |
Mci-186 |
Edaravone |
D01552 |
- |
- |
1件: 2 |
220 |
Mci-186 in open label phase |
Edaravone |
D01552 |
- |
- |
1件: 2 |
221 |
Md1003 |
- |
- |
- |
- |
5件: 2, 10, 13, 14, 20 |
222 |
Mecobalamin |
Methylcobalamin |
D03246 |
- |
- |
1件: 2 |
223 |
Medicine |
- |
- |
- |
- |
1件: 2 |
224 |
Memantine |
Memantine |
D04905, D08174 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
7件: 2, 6, 8, 13, 49, 127, 205 |
225 |
Memantine (ebixa) |
Memantine |
D04905, D08174 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 2 |
226 |
Memantine hydrochloride |
Memantine |
D04905, D08174 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
3件: 2, 6, 127 |
227 |
Mesenchymal stem cell |
- |
- |
- |
- |
2件: 2, 93 |
228 |
Mesenchymal stem cells |
- |
- |
- |
- |
11件: 2, 6, 13, 20, 49, 51, 60, 96, 222, 274, 299 |
229 |
Methylcobalamin |
Methylcobalamin |
D03246 |
- |
- |
1件: 2 |
230 |
Methylprednisolone |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
36件: 2, 13, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 145, 164, 220, 222, 224, 271, 283, 284, 285, 296 |
231 |
Mexiletine |
Mexiletine |
D00639, D08215 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
5件: 1, 2, 10, 113, 114 |
232 |
Midazolam |
Midazolam |
D00550, D00696, D05028 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
10件: 2, 3, 6, 13, 46, 70, 96, 97, 231, 298 |
233 |
Minocycline |
Minocycline |
D00850, D05045 |
- |
- |
13件: 2, 6, 8, 13, 46, 85, 90, 94, 162, 201, 206, 280, 299 |
234 |
Mn-166 |
- |
- |
- |
- |
1件: 2 |
235 |
Monitor |
Methamidophos |
- |
- |
- |
12件: 2, 11, 13, 19, 46, 49, 58, 70, 85, 98, 298, 300 |
236 |
Monthly autologous treg cells infusions + 3 times per week interleukin-2 injections |
Human interleukin-2 |
- |
- |
- |
1件: 2 |
237 |
Moxifloxacin |
Moxifloxacin |
D00874, D08237 |
- |
- |
8件: 2, 6, 46, 49, 85, 86, 240, 299 |
238 |
Msc-ntf cells transplantation (im) |
- |
- |
- |
- |
1件: 2 |
239 |
Msc-ntf cells transplantation (it) |
- |
- |
- |
- |
1件: 2 |
240 |
Msc_ntf cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the csf |
- |
- |
- |
- |
1件: 2 |
241 |
Multiple dose |
- |
- |
- |
- |
1件: 2 |
242 |
Mycophenolate |
Mycophenolic acid |
D05096 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
33件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
243 |
Mycophenolate mofetil |
Mycophenolate mofetil |
D00752, D05094, D05095 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
32件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
244 |
Myelostim 34*1fl 263mcg+1sir |
- |
- |
- |
- |
1件: 2 |
245 |
Myonal*30cpr riv 100mg |
- |
- |
- |
- |
1件: 2 |
246 |
Np001 |
- |
- |
- |
- |
1件: 2 |
247 |
Nuedexta |
Dextromethorphan |
D00848, D03742, D03744 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 2 |
248 |
Nurown® (msc-ntf cells) |
- |
- |
- |
- |
1件: 2 |
249 |
Odm-109 |
- |
- |
- |
- |
1件: 2 |
250 |
Odm-109 capsule 1 mg |
- |
- |
- |
- |
1件: 2 |
251 |
Olanzapine |
Olanzapine |
D00454, D06623 |
11件: ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR2A, HTR2B, HTR2C, HTR6 |
16件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Salivary secretion, Serotonergic synapse, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
2件: 2, 8 |
252 |
Olesoxime |
- |
- |
- |
- |
2件: 2, 3 |
253 |
Ono-2506po |
- |
- |
- |
- |
2件: 2, 6 |
254 |
Oral levosimendan |
Levosimendan |
D04720 |
2件: PDE3A, PDE3B |
11件: Apelin signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Progesterone-mediated oocyte maturation, Purine metabolism, Regulation of lipolysis in adipocytes, Renin secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 2 |
255 |
Oral nutritional supplementation |
- |
- |
- |
- |
1件: 2 |
256 |
Oxepa |
- |
- |
- |
- |
1件: 2 |
257 |
Ozanezumab |
Ozanezumab |
D10331 |
1件: RTN4 |
1件: Alzheimer disease |
1件: 2 |
258 |
Palmitoylethanolamide |
Palmidrol |
D08328 |
- |
- |
1件: 2 |
259 |
Paracetamolo |
- |
- |
- |
- |
1件: 2 |
260 |
Pbmc autotransplantation |
- |
- |
- |
- |
1件: 2 |
261 |
Perampanel |
Perampanel |
D08964 |
4件: GRIA1, GRIA2, GRIA3, GRIA4 |
13件: Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Transcriptional misregulation in cancer, cAMP signaling pathway |
3件: 2, 6, 144 |
262 |
Perfalgan |
- |
- |
- |
- |
1件: 2 |
263 |
Phenylbutyrate |
Phenylbutyric acid |
D05868 |
- |
- |
10件: 2, 3, 6, 8, 93, 94, 244, 251, 297, 299 |
264 |
Phosphate |
Phosphate ion |
- |
- |
- |
29件: 2, 3, 11, 12, 13, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 256, 283, 284, 285, 286, 299 |
265 |
Pimozide |
Pimozide |
D00560 |
2件: DRD2, DRD3 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 2 |
266 |
Pimozide 2 mg per day |
Pimozide |
D00560 |
2件: DRD2, DRD3 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 2 |
267 |
Pimozide 2mg/day (current) or 4 mg/day (study initiation) |
Pimozide |
D00560 |
2件: DRD2, DRD3 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 2 |
268 |
Pimozide 4 mg per day |
Pimozide |
D00560 |
2件: DRD2, DRD3 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 2 |
269 |
Pioglitazone |
Pioglitazone |
D00945, D08378 |
1件: PPARG |
9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
270 |
Pioglitazone and tretinoin |
Pioglitazone |
D00945, D08378 |
1件: PPARG |
9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
1件: 2 |
271 |
Pleconaril |
Pleconaril |
D05528 |
- |
- |
1件: 2 |
272 |
Plenur |
- |
- |
- |
- |
1件: 2 |
273 |
Pramipexole |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
2件: 2, 6 |
274 |
Prednisone |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
43件: 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
275 |
Probiotic |
- |
- |
- |
- |
5件: 2, 6, 96, 193, 266 |
276 |
Proleukin |
Aldesleukin |
D00748 |
3件: IL2RA, IL2RB, IL2RG |
14件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor |
2件: 2, 49 |
277 |
Proleukin 18 mui |
Aldesleukin |
D00748 |
3件: IL2RA, IL2RB, IL2RG |
14件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor |
1件: 2 |
278 |
Prototype capsule gdc-0134 |
- |
- |
- |
- |
1件: 2 |
279 |
Pyrimethamine |
Pyrimethamine |
D00488 |
- |
- |
4件: 2, 4, 19, 65 |
280 |
Q-cells |
- |
- |
- |
- |
1件: 2 |
281 |
Quinidine |
Quinidine |
D00642, D00643, D02272, D08458 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
3件: 2, 8, 13 |
282 |
R(+) pramipexole dihydrochloride monohydrate |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 2 |
283 |
Rabeprazole |
Rabeprazole |
D00724, D08463 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
2件: 2, 51 |
284 |
Ranolazine |
Ranolazine |
D05700, D05701 |
- |
- |
6件: 2, 58, 86, 113, 114, 130 |
285 |
Ranolazine 1000 mg |
Ranolazine |
D05700, D05701 |
- |
- |
1件: 2 |
286 |
Ranolazine 500 mg |
Ranolazine |
D05700, D05701 |
- |
- |
1件: 2 |
287 |
Rapamune |
Sirolimus |
D00753 |
1件: MTOR |
43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
5件: 2, 60, 66, 67, 158 |
288 |
Rapamune - 1 mg 100 compresse rivestite in blister uso orale |
Sirolimus |
D00753 |
1件: MTOR |
43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
1件: 2 |
289 |
Rapamycin |
Sirolimus |
D00753 |
1件: MTOR |
43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
16件: 2, 15, 34, 35, 46, 49, 51, 60, 61, 67, 86, 89, 158, 256, 278, 279 |
290 |
Rasagiline |
Rasagiline |
D02562, D08469, D10829 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
4件: 2, 5, 6, 17 |
291 |
Rasagiline mesilate |
Rasagiline |
D02562, D08469, D10829 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
3件: 2, 5, 6 |
292 |
Recombinant human erythropoietin(rhepo) |
Erythropoietin |
D03231 |
1件: EPOR |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
1件: 2 |
293 |
Reference capsule gdc-0134 |
- |
- |
- |
- |
1件: 2 |
294 |
Repository corticotropin injection |
Corticotropin |
D00146 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
5件: 2, 13, 46, 84, 222 |
295 |
Requip cr tablets |
- |
- |
- |
- |
1件: 2 |
296 |
Retigabine |
Ezogabine |
D09569 |
5件: KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5 |
6件: Adrenergic signaling in cardiomyocytes, Cholinergic synapse, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Vibrio cholerae infection |
2件: 2, 144 |
297 |
Ribavirin |
Ribavirin |
D00423 |
- |
- |
2件: 2, 96 |
298 |
Rilutek |
Riluzole |
D00775 |
14件: GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway |
1件: 2 |
299 |
Rilutek 50 mg film-coated tablets |
Riluzole |
D00775 |
14件: GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway |
1件: 2 |
300 |
Rilutek 50 mg, film-coated tablets |
Riluzole |
D00775 |
14件: GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway |
1件: 2 |
301 |
Riluzole |
Riluzole |
D00775 |
14件: GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway |
7件: 2, 3, 5, 8, 13, 17, 206 |
302 |
Riluzole 50 mg |
Riluzole |
D00775 |
14件: GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway |
1件: 2 |
303 |
Riluzole 50 mg (part b) |
Riluzole |
D00775 |
14件: GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway |
1件: 2 |
304 |
Riluzole oral soluble film |
Riluzole |
D00775 |
14件: GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway |
1件: 2 |
305 |
Riluzole oral soluble film (rosf) 50 mg |
Riluzole |
D00775 |
14件: GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway |
1件: 2 |
306 |
Riluzolo |
- |
- |
- |
- |
1件: 2 |
307 |
Ritonavir |
Ritonavir |
D00427 |
- |
- |
4件: 2, 86, 130, 265 |
308 |
Rns60 |
- |
- |
- |
- |
2件: 2, 13 |
309 |
Saline solution |
- |
- |
- |
- |
4件: 2, 34, 288, 299 |
310 |
Sativex |
Dronabinol |
D00306 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
2件: 2, 13 |
311 |
Sb-509 |
- |
- |
- |
- |
1件: 2 |
312 |
Scopolamine |
Scopolamine |
D00138 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
1件: 2 |
313 |
Selective serotonin uptake inhibitors (ssri) |
Serotonin |
- |
- |
- |
1件: 2 |
314 |
Serine |
Serine |
D00016 |
- |
- |
3件: 2, 6, 86 |
315 |
Serotonin |
Serotonin |
- |
- |
- |
1件: 2 |
316 |
Single dose reduced |
- |
- |
- |
- |
1件: 2 |
317 |
Single dose standard |
- |
- |
- |
- |
1件: 2 |
318 |
Snn0029 |
- |
- |
- |
- |
1件: 2 |
319 |
Snn0029 infusion solution |
- |
- |
- |
- |
1件: 2 |
320 |
Sodium phenylbutyrate |
Phenylbutyric acid |
D05868 |
- |
- |
4件: 2, 3, 8, 251 |
321 |
Sodium valproate |
Valproic acid |
D00399 |
7件: ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 |
17件: Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
4件: 2, 90, 102, 256 |
322 |
Somatropin |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
15件: 2, 3, 19, 46, 74, 75, 78, 96, 113, 193, 195, 265, 274, 276, 299 |
323 |
Spect : 123 i-fp-cit (datscan) and 123i-adam |
- |
- |
- |
- |
1件: 2 |
324 |
Spirit1 |
- |
- |
- |
- |
1件: 2 |
325 |
Stem cell |
- |
- |
- |
- |
2件: 2, 113 |
326 |
Stem cell (hpc) implantation |
- |
- |
- |
- |
1件: 2 |
327 |
Stem cells |
- |
- |
- |
- |
4件: 2, 4, 96, 113 |
328 |
Sulfate |
Sulfate ion |
- |
- |
- |
22件: 2, 6, 11, 13, 26, 34, 36, 46, 49, 60, 61, 64, 66, 79, 86, 96, 222, 226, 265, 296, 297, 299 |
329 |
Suspension of human autologous msc 3p in 1,5 ml |
- |
- |
- |
- |
1件: 2 |
330 |
Suspension of human autologous msc 3p in 1.5 ml |
- |
- |
- |
- |
1件: 2 |
331 |
Tacrolimus |
Tacrolimus |
D00107, D08556 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
29件: 2, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 228, 283, 284, 299 |
332 |
Talampanel |
Talampanel |
D02696 |
4件: GRIA1, GRIA2, GRIA3, GRIA4 |
13件: Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Transcriptional misregulation in cancer, cAMP signaling pathway |
2件: 2, 6 |
333 |
Tamoxifen |
Tamoxifen |
D00966, D08559 |
2件: ESR1, ESR2 |
9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
4件: 2, 86, 113, 227 |
334 |
Tamoxifen 40 mg daily for one year |
Tamoxifen |
D00966, D08559 |
2件: ESR1, ESR2 |
9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
1件: 2 |
335 |
Tauroursodeoxycholic acid |
Tauroursodeoxycholic acid |
- |
- |
- |
4件: 2, 13, 93, 299 |
336 |
Tch346 |
- |
- |
- |
- |
1件: 2 |
337 |
Tenofovir |
Tenofovir |
D06074 |
- |
- |
5件: 2, 25, 93, 265, 325 |
338 |
Tenofovir alafenamide |
Tenofovir alafenamide |
D10428 |
- |
- |
1件: 2 |
339 |
Tenofovir alafenamide (taf) |
Tenofovir alafenamide |
D10428 |
- |
- |
1件: 2 |
340 |
Testosterone |
Testosterone |
D00075, D00957, D00958, D00959, D06085, D06087 |
1件: AR |
3件: Oocyte meiosis, Pathways in cancer, Prostate cancer |
7件: 1, 2, 3, 13, 78, 113, 265 |
341 |
Tevagrastim |
- |
- |
- |
- |
1件: 2 |
342 |
Thalidomide |
Thalidomide |
D00754 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
343 |
Thalidomide (drug) |
Thalidomide |
D00754 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 2 |
344 |
Tioctic acid |
- |
- |
- |
- |
1件: 2 |
345 |
Tirasemtiv |
Tirasemtiv |
D10327 |
- |
- |
1件: 2 |
346 |
Tocilizumab |
Tocilizumab |
D02596 |
1件: IL6R |
11件: Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease (NAFLD), PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
347 |
Tocotrienols |
- |
- |
- |
- |
1件: 2 |
348 |
Tretinoin |
Tretinoin |
D00094 |
3件: PML, RARA, RARB |
12件: Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Influenza A, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis |
2件: 2, 75 |
349 |
Tretinoin and pioglitazone hcl |
Pioglitazone |
D00945, D08378 |
1件: PPARG |
9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
1件: 2 |
350 |
Tricyclic antidepressants (tca) |
- |
- |
- |
- |
1件: 2 |
351 |
Triheptanoin |
Triheptanoin |
D11465 |
- |
- |
10件: 2, 8, 120, 149, 156, 248, 256, 257, 317, 324 |
352 |
Triumeq |
Lamivudine |
D00353 |
- |
- |
1件: 2 |
353 |
Tro19622 |
Tro19622 |
- |
- |
- |
3件: 2, 3, 13 |
354 |
Trobalt |
Ezogabine |
D09569 |
5件: KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5 |
6件: Adrenergic signaling in cardiomyocytes, Cholinergic synapse, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Vibrio cholerae infection |
1件: 2 |
355 |
Tv-7110 |
- |
- |
- |
- |
1件: 2 |
356 |
Téralithe lp |
- |
- |
- |
- |
1件: 2 |
357 |
Valproate |
Valproic acid |
D00399 |
7件: ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 |
17件: Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
6件: 2, 3, 90, 102, 233, 256 |
358 |
Vitamin e |
Vitamin e |
D02331 |
- |
- |
11件: 2, 6, 13, 20, 46, 90, 96, 97, 206, 299, 317 |
359 |
Vm202 |
- |
- |
- |
- |
1件: 2 |
360 |
Water |
Water |
D00001 |
- |
- |
18件: 2, 5, 6, 13, 17, 19, 35, 46, 53, 57, 63, 65, 67, 84, 97, 226, 278, 299 |
361 |
Yam80 |
- |
- |
- |
- |
1件: 2 |
362 |
Zibren*20bust 500mg |
- |
- |
- |
- |
1件: 2 |
363 |
Zinc |
Zinc |
- |
- |
- |
4件: 2, 19, 171, 299 |
364 |
Zinc and copper |
Copper |
- |
- |
- |
1件: 2 |
365 |
Zyprexa |
Olanzapine |
D00454, D06623 |
11件: ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR2A, HTR2B, HTR2C, HTR6 |
16件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Salivary secretion, Serotonergic synapse, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 2 |